Mark J Mckeage

List of Publications by Year
in descending order

98 papers	4,690 citations	109321 35 h-index	102487 66 g-index
99 all docs	99 docs citations	99 times ranked	5538 citing authors

#	Article	IF	Citations
1	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Nonâ€“Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clinical Cancer Research, 2022, 28, 2506-2516.	7.0	19
2	Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in nonâ€smallâ€cell lung cancer in New Zealand. Internal Medicine Journal, 2020, 50, 716-725.	0.8	9
3	Muscle ultrasound in the assessment of oxaliplatin-induced neurotoxicity. Clinical Neurophysiology, 2020, 131, 343-344.	1.5	4
4	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study ofÂCeritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, 609-617.	1.1	27
5	Osimertinib in NSCLC: Real-World Data From NewÂZealand. JTO Clinical and Research Reports, 2020, 1, 100022.	1.1	3
6	Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review. Targeted Oncology, 2020, 15, 279-299.	3.6	14
7	Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells. Cancers, 2019, 11, 1330.	3.7	17
8	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)â€“Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. Journal of Thoracic Oncology, 2019, 14, 1255-1265.	1.1	59
9	Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer. Scientific Reports, 2019, 9, 2245.	3.3	18
10	Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Targeted Oncology, 2018, 13, 89-98.	3.6	63
11	Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand. Cancer Epidemiology, 2018, 57, 24-32.	1.9	8
12	The Effects of Synthetically Modified Natural Compounds on ABC Transporters. Pharmaceutics, 2018, 10, 127.	4.5	19
13	Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity. Journal of Inorganic Biochemistry, 2017, 177, 249-258.	3.5	17
14	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Nonâ€“Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, 1357-1367.	1.1	144
15	Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation. Scientific Reports, 2017, 7, 4073.	3.3	8
16	EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. Targeted Oncology, 2017, 12, 663-675.	3.6	12
17	Lung cancer mutation testing: a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test. Oncotarget, 2017, 8, 101437-101451.	1.8	12
18	Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1479-1490.	3.3	17

#	Article	IF	Citations
19	Role of platinum DNA damageâ€induced transcriptional inhibition in chemotherapyâ€induced neuronal atrophy and peripheral neurotoxicity. Journal of Neurochemistry, 2015, 135, 1099-1112.	3.9	31
20	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS ONE, 2015, 10, e0130727.	2.5	32
21	Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. Journal of Structural Biology, 2015, 192, 539-544.	2.8	106
22	Therapeutic targeting of tumor angiogenesis: how far have we come?. Clinical Investigation, 2014, 4, 1113-1122.	0.0	0
23	Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs. Frontiers in Oncology, 2014, 4, 221.	2.8	23
24	Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. Cancer Chemotherapy and Pharmacology, 2014, 74, 25-35.	2.3	8
25	Emerging roles of metal solute carriers in cancer mechanisms and treatment. Biopharmaceutics and Drug Disposition, 2014, 35, 450-462.	1.9	13
26	Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy. Current Cancer Therapy Reviews, 2014, 9, 236-244.	0.3	0
27	Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. BMC Cancer, 2013, 13, 495.	2.6	20
28	Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. Biochemical Pharmacology, 2013, 85, 207-215.	4.4	34
29	Evaluation of effects of copper histidine on copper transporter 1â€mediated accumulation of platinum and oxaliplatinâ€induced neurotoxicity in vitro and in vivo. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 371-378.	1.9	10
30	Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs. Current Cancer Drug Targets, 2012, 12, 962-986.	1.6	55
31	Reply to E.S. Wang et al. Journal of Clinical Oncology, 2012, 30, 761-762.	1.6	7
32	Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence. Clinical Investigation, 2012, 2, 985-993.	0.0	11
33	PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. BMC Cancer, 2012, 12, 496.	2.6	49
34	Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial. Cancer Chemotherapy and Pharmacology, 2012, 69, 1145-1154.	2.3	5
35	Neuropathies associated with oxaliplatin therapy. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 107-110.	1.1	4
36	A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer, 2011, 11, 432.	2.6	56

#	Article	IF	Citations
37	Clinical Trials of Vascular Disrupting Agents in Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2011, 12, 143-147.	2.6	12
38	Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 2965-2971.	1.6	282
39	A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma. Clinical Cancer Research, 2011, 17, 1998-2005.	7.0	82
40	Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 537-547.	2.5	112
41	Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer, 2010, 10, 451.	2.6	42
42	Disrupting established tumor blood vessels. Cancer, 2010, 116, 1859-1871.	4.1	138
43	ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. Future Oncology, 2010, 6, 1537-1543.	2.4	16
44	Differential Expression of ATP7A, ATP7B and CTR1 in Adult Rat Dorsal Root Ganglion Tissue. Molecular Pain, 2010, 6, 1744-8069-6-53.	2.1	30
45	Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. Journal of Thoracic Disease, 2010, 2, 199-204.	1.4	30
46	Transient Retinal Effects of 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA, ASA404), an Antitumor Vascular-Disrupting Agent in Phase I Clinical Trials. , 2009, 50, 2553.		14
47	Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemotherapy and Pharmacology, 2009, 64, 847-856.	2.3	49
48	Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer, 2009, 65, 192-197.	2.0	92
49	Oxaliplatin-Induced Loss of Phosphorylated Heavy Neurofilament Subunit Neuronal Immunoreactivity in Rat Drg Tissue. Molecular Pain, 2009, 5, 1744-8069-5-66.	2.1	27
50	In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. Journal of Inorganic Biochemistry, 2008, 102, 303-310.	3.5	174
51	Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. British Journal of Cancer, 2008, 99, 2006-2012.	6.4	129
52	COMPARATIVE PROTEIN BINDING, STABILITY AND DEGRADATION OF SATRAPLATIN, JM118 AND CISPLATIN IN HUMAN PLASMA IN VITRO. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 1440-1446.	1.9	20
53	Platinum-specific detection and quantification of oxaliplatin and Pt(R,R-diaminocyclohexane)Cl2 in the blood plasma of colorectal cancer patients. Journal of Analytical Atomic Spectrometry, 2008, 23, 881.	3.0	22
54	The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opinion on Investigational Drugs, 2008, 17, 23-29.	4.1	32

#	Article	IF	Citations
55	Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. NeuroToxicology, 2007, 28, 1092-1098.	3.0	29
56	Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types. Drugs, 2007, 67, 859-869.	10.9	15
57	Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 99-105.	1.1	6
58	Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemotherapy and Pharmacology, 2007, 59, 661-669.	2.3	20
59	5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA). American Journal of Cancer, 2006, 5, 155-162.	0.4	18
60	Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 837, 29-34.	2.3	39
61	Satraplatin activation by haemoglobin, cytochrome C and liver microsomes inÂvitro. Cancer Chemotherapy and Pharmacology, 2006, 57, 483-490.	2.3	83
62	5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent. Clinical Cancer Research, 2006, 12, 1776-1784.	7.0	90
63	Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemotherapy and Pharmacology, 2005, 56, 391-399.	2.3	105
64	New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opinion on Investigational Drugs, 2005, 14, 1033-1046.	4.1	42
65	Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients*. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 677-682.	1.9	14
66	Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemotherapy and Pharmacology, 2003, 51, 43-52.	2.3	95
67	Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. British Journal of Cancer, 2003, 88, 1942-1947.	6.4	23
68	Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemotherapy and Pharmacology, 2002, 50, 9-15.	2.3	87
69	Examination of the effects of oxidation and ring closure on the cytotoxicities of the platinum complexes of N-(2-hydroxyethyl)ethane-1,2-diamine and ethane-1,2-diamine-N,Nâ€²-diacetic acid. Journal of Inorganic Biochemistry, 2002, 91, 205-211.	3.5	12
70	Gold opens mitochondrial pathways to apoptosis. British Journal of Pharmacology, 2002, 136, 1081-1082.	5.4	24
71	Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria. Coordination Chemistry Reviews, 2002, 232, 127-135.	18.8	230
72	Lobaplatin: a new antitumour platinum drug. Expert Opinion on Investigational Drugs, 2001, 10, 119-128.	4.1	138

#	Article	IF	Citations
73	cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: synthesis and action in resistant cell lines in vitro. Journal of Inorganic Biochemistry, 2001, 85, 209-217.	3.5	50
74	Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. British Journal of Cancer, 2001, 85, 1219-1225.	6.4	100
75	Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemotherapy and Pharmacology, 2000, 46, 343-350.	2.3	197
76	Increased targeting of adenine-rich sequences by (2-amino-2-methyl-3-butanone) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td (oxime)di Inorganic Chemistry, 2000, 5, 675-681.	2.6	20
77	Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. Journal of Inorganic Biochemistry, 1999, 77, 105-110.	3.5	138
78	Structural and solution chemistry of gold(I) and silver(I) complexes of bidentate pyridyl phosphines: selective antitumour agents. Coordination Chemistry Reviews, 1999, 185-186, 823-836.	18.8	115
79	Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin. Cancer Investigation, 1999, 17, 479-485.	1.3	3
80	Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation. Journal of Analytical Atomic Spectrometry, 1999, 14, 953-956.	3.0	31
81	Antitumor Activity of Gold(I), Silver(I) and Copper(I) Complexes Containing Chiral Tertiary Phosphines. Metal-Based Drugs, 1998, 5, 217-223.	3.8	65
82	Preparation, Characterization, DNA Binding, and in Vitro Cytotoxicity of the Enantiomers of the Platinum(II) Complexes N-Methyl-, N-Ethyl- and N,N-Dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II). Journal of Medicinal Chemistry, 1997, 40, 3508-3515.	6.4	34
83	Preparation, DNA Binding, andin VitroCytotoxicity of a Pair of Enantiomeric Platinum(II) Complexes, [(R)- and (S)-3-Aminohexahydroazepine]dichloro- platinum(II). Crystal Structure of theSEnantiomer. Journal of Medicinal Chemistry, 1997, 40, 1090-1098.	6.4	65
84	Selective antitumour activity of metal complexes of bidentate pyridylphosphines. Journal of Inorganic Biochemistry, 1997, 67, 154.	3.5	8
85	The Clinical Development of the Oral Platinum Anticancer Agent JM216. , 1996, , 83-89.		4
86	A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemotherapy and Pharmacology, 1995, 36, 451-458.	2.3	93
87	Comparative Adverse Effect Profiles of Platinum Drugs. Drug Safety, 1995, 13, 228-244.	3.2	271
88	Non-surgical aspects of ovarian cancer. Lancet, The, 1994, 343, 335-340.	13.7	17
89	Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. Cancer Chemotherapy and Pharmacology, 1994, 33, 497-503.	2.3	19
90	New Platinum Agents. Drugs and Aging, 1994, 5, 85-95.	2.7	16

#	Article	IF	Citations
91	Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro. British Journal of Cancer, 1994, 69, 1-7.	6.4	19
92	Preclinical toxicology and tissue platinum distribution of novel?oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. Cancer Chemotherapy and Pharmacology, 1994, 33, 497-503.	2.3	2
93	Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. British Journal of Cancer, 1993, 67, 996-1000.	6.4	38
94	Tamoxifen and Chemotherapy for Refractory Metastatic Malignant Melanoma. New England Journal of Medicine, 1993, 328, 140-141.	27.0	8
95	New Platinum Drugs. , 1993, , 169-212.		7
96	A clinical and pharamcological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue. Cancer Chemotherapy and Pharmacology, 1992, 29, 201-206.	2.3	2
97	Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemotherapy and Pharmacology, 1991, 28, 409-413.	2.3	31
98	Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-methyl-xanthenone-4-acetic acid and flavone acetic acid. Cancer Chemotherapy and Pharmacology, 1991, 28, 414-419.	2.3	8